Amit Hazan
Stock Analyst at Goldman Sachs
(2.09)
# 2,948
Out of 5,116 analysts
95
Total ratings
56.25%
Success rate
1.33%
Average return
Main Sectors:
Stocks Rated by Amit Hazan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSP Inspire Medical Systems | Upgrades: Buy | n/a | $95.47 | - | 3 | Dec 13, 2022 | |
| BVS Bioventus | Maintains: Neutral | $13 → $2.5 | $7.46 | -66.49% | 5 | Nov 30, 2022 | |
| SKIN The Beauty Health Company | Maintains: Buy | $22 → $19 | $1.46 | +1,201.37% | 4 | Nov 23, 2022 | |
| SHC Sotera Health Company | Maintains: Neutral | $9 → $8 | $17.70 | -54.80% | 4 | Nov 23, 2022 | |
| LIVN LivaNova | Maintains: Buy | $73 → $63 | $62.87 | +0.21% | 3 | Nov 23, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Buy | $319 → $272 | $196.33 | +38.54% | 8 | Nov 23, 2022 | |
| BLCO Bausch + Lomb | Maintains: Neutral | $19 → $17 | $17.18 | -1.05% | 3 | Nov 23, 2022 | |
| OM Outset Medical | Maintains: Buy | $510 → $435 | $3.36 | +12,846.43% | 2 | Nov 9, 2022 | |
| PRCT PROCEPT BioRobotics | Maintains: Neutral | $39 → $44 | $32.41 | +35.76% | 2 | Nov 4, 2022 | |
| EW Edwards Lifesciences | Maintains: Neutral | $97 → $73 | $86.85 | -15.95% | 3 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $60 → $53 | $19.38 | +173.48% | 11 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $57 | $27.39 | +108.11% | 1 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $9.5 | $20.97 | -54.69% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $111 → $104 | $124.84 | -16.69% | 7 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $60 | $16.49 | +263.86% | 3 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $129 → $115 | $96.52 | +19.15% | 9 | Jan 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $248 → $150 | $354.22 | -57.65% | 2 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $46 | $96.06 | -52.11% | 1 | Feb 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $242 | $577.81 | -58.17% | 8 | Feb 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $177 | $90.77 | +95.00% | 5 | Feb 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $139 → $147 | $207.63 | -29.20% | 6 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $3.5 → $3.9 | $0.83 | +372.56% | 3 | Nov 1, 2018 |
Inspire Medical Systems
Dec 13, 2022
Upgrades: Buy
Price Target: n/a
Current: $95.47
Upside: -
Bioventus
Nov 30, 2022
Maintains: Neutral
Price Target: $13 → $2.5
Current: $7.46
Upside: -66.49%
The Beauty Health Company
Nov 23, 2022
Maintains: Buy
Price Target: $22 → $19
Current: $1.46
Upside: +1,201.37%
Sotera Health Company
Nov 23, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $17.70
Upside: -54.80%
LivaNova
Nov 23, 2022
Maintains: Buy
Price Target: $73 → $63
Current: $62.87
Upside: +0.21%
Becton, Dickinson and Company
Nov 23, 2022
Maintains: Buy
Price Target: $319 → $272
Current: $196.33
Upside: +38.54%
Bausch + Lomb
Nov 23, 2022
Maintains: Neutral
Price Target: $19 → $17
Current: $17.18
Upside: -1.05%
Outset Medical
Nov 9, 2022
Maintains: Buy
Price Target: $510 → $435
Current: $3.36
Upside: +12,846.43%
PROCEPT BioRobotics
Nov 4, 2022
Maintains: Neutral
Price Target: $39 → $44
Current: $32.41
Upside: +35.76%
Edwards Lifesciences
Nov 3, 2022
Maintains: Neutral
Price Target: $97 → $73
Current: $86.85
Upside: -15.95%
Nov 3, 2022
Maintains: Sell
Price Target: $60 → $53
Current: $19.38
Upside: +173.48%
Oct 11, 2022
Initiates: Buy
Price Target: $57
Current: $27.39
Upside: +108.11%
Aug 8, 2022
Maintains: Neutral
Price Target: $11 → $9.5
Current: $20.97
Upside: -54.69%
Jul 25, 2022
Maintains: Sell
Price Target: $111 → $104
Current: $124.84
Upside: -16.69%
Jul 14, 2022
Maintains: Neutral
Price Target: $80 → $60
Current: $16.49
Upside: +263.86%
Jan 18, 2022
Maintains: Neutral
Price Target: $129 → $115
Current: $96.52
Upside: +19.15%
Apr 1, 2020
Downgrades: Sell
Price Target: $248 → $150
Current: $354.22
Upside: -57.65%
Feb 13, 2020
Initiates: Neutral
Price Target: $46
Current: $96.06
Upside: -52.11%
Feb 13, 2020
Initiates: Buy
Price Target: $242
Current: $577.81
Upside: -58.17%
Feb 13, 2020
Initiates: Buy
Price Target: $177
Current: $90.77
Upside: +95.00%
Feb 25, 2019
Maintains: Neutral
Price Target: $139 → $147
Current: $207.63
Upside: -29.20%
Nov 1, 2018
Upgrades: Neutral
Price Target: $3.5 → $3.9
Current: $0.83
Upside: +372.56%